The recent success of Imitrex-the antimigraine drug made by Glaxo Wellcome Inc. of Research Triangle Park, N.C.-has ignited a fury of pharmaceutical research. Imitrex (generic: sumatriptan) is the first serotonin (5-HT) agonist, or mimic, made to fight migraines. In 1996, Imitrex tablets reaped $840 million in worldwide sales. Now, a half-dozen companies are creating new brands of migraine relief-and opening the door to neuroscientists and molecular biologists in the process.
A TRAILBLAZER: The usccess of Imitrex, the migraine drug from Glaxo Wellcome that reaped $840 million in sales last year, has promped other companies to develop similar drugs.
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?